Intravesical immunotherapy in nonmuscle invasive bladder cancer

Indian Journal of Urology

Volumn 31, Issue 4, 2015, Pages 304-311

  Jokisch, Jan Friedrich ^a   Karl, Alexander ^a   Stief, Christian ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Bacillus Calmette Guerin; bladder cancer; immunotherapy

Indexed keywords

ALPHA INTERFERON; AMINOLEVULINIC ACID; ANTINEOPLA; ANTINEOPLASTIC AGENT; BCG VACCINE; CANCER VACCINE; EPIRUBICIN; IMMUNE CHECKPOINT INHIBITOR; INTERLEUKIN 10 ANTIBODY; MITOMYCIN; MYCOBACTERIUM PHLEI CELL WALL NUCLEIC ACID COMPLEX; PHOTOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; NON MUSCLE INVASIVE BLADDER CANCER; PHOTODYNAMIC THERAPY; REVIEW; RISK BENEFIT ANALYSIS;

EID: 84973539351     PISSN: 09701591     EISSN: 19983824     Source Type: Journal    
DOI: 10.4103/0970-1591.166452     Document Type: Review

References (56)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Sievert KD, Amend B, Nagele U, Schilling D, Bedke J, Horstmann M, et al. Economic aspects of bladder cancer: What are the benefits and costs? World J Urol 2009;27:295-300.
3. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2013. Eur Urol. 2013;64:639-53.
4. Witjes JA, Palou J, Soloway M, Lamm D, Kamat AM, Brausi M, et al. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): Results of an international individual patient data survey (IPDS). BJU Int 2013;112:742-50.
5. Chamie K, Saigal CS, Lai J, Hanley JM, Setodji CM, Konety BR, et al. Compliance with guidelines for patients with bladder cancer: Variation in the delivery of care. Cancer 2011;117:5392-401.
6. Morales A, Eidinger D, Bruce AW. Intracavitary bacillus calmetteguerin in the treatment of superficial bladder tumors. J Urol 1976;116:180-3.
7. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus calmette-guerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials. J Urol 2002;168:1964-70.
8. Alexandroff AB, Jackson AM, O'Donnell MA, James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet 1999;353:1689-94.
9. Fuge O, Vasdev N, Allchorne P, Green JS. Immunotherapy for bladder cancer. Res Rep Urol 2015;7:65-79.
10. Kavoussi LR, Brown EJ, Ritchey JK, Ratliff TL. Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. J Clin Invest 1990;85:62-7.
11. Lattime EC, Gomella LG, McCue PA. Murine bladder carcinoma cells present antigen to BCG-specific CD4 T-cells. Cancer Res 1992;52:4286-90.
12. Noon AP, Kulkarni GS. All bacillus Calmette-Guérin (BCG) strains are equal, but some BCG strains are more equal than others. Eur Urol 2014;66:689-91.
13. Rentsch CA, Birkhäuser FD, Biot C, Gsponer JR, Bisiaux A, Wetterauer C, et al. Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. Eur Urol 2014;66:677-88.
14. Järvinen R, Kaasinen E, Sankila A, Rintala E; FinnBladder Group. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: A subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. Eur Urol 2009;56:260-5.
15. Duchek M, Johansson R, Jahnson S, Mestad O, Hellström P, Hellsten S, et al. Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study. Eur Urol 2010;57:25-31.
16. Shang PF, Kwong J, Wang ZP, Tian J, Jiang L, Yang K, et al. Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer. Cochrane Database Syst Rev 2011;5:CD006885.
17. Lamm DL. Bacillus Calmette-Guerin immunotherapy for bladder cancer. J Urol 1985;134:40-7.
18. Pinsky CM, Camacho FJ, Kerr D, Geller NL, Klein FA, Herr HA, et al. Intravesical administration of bacillus Calmette-Guérin in patients with recurrent superficial carcinoma of the urinary bladder: Report of a prospective, randomized trial. Cancer Treat Rep 1985;69:47-53.
19. Böhle A, Bock PR. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: Formal meta-analysis of comparative studies on tumor progression. Urology 2004;63:682-6.
20. Oddens J, Brausi M, Sylvester R, Bono A, van de Beek C, van Andel G, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: One-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 2013;63:462-72.
21. De Jager R, Guinan P, Lamm D, Khanna O, Brosman S, De Kernion J, et al. Long-term complete remission in bladder carcinoma in situ with intravesical TICE bacillus Calmette Guerin. Overview analysis of six phase II clinical trials. Urology. 1991;38:507-13.
22. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group Study. J Urol 2000;163:1124-9.
23. Herr HW, Dalbagni G, Donat SM. Bacillus Calmette-Guérin without maintenance therapy for high-risk non-muscle-invasive bladder cancer. Eur Urol 2011;60:32-6.
24. Zlotta AR, van Vooren JP, Huygen K, Drowart A, Decock M, Pirson M, et al. What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary? Eur Urol 2000;37:470-7.
25. Brausi M, Oddens J, Sylvester R, Bono A, van de Beek C, van Andel G, et al. Side effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: Results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol 2014;65:69-76.
26. Ojea A, Nogueira JL, Solsona E, Flores N, Gómez JM, Molina JR, et al. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: Low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur Urol 2007;52:1398-406.
27. Martínez-Piñeiro JA, Flores N, Isorna S, Solsona E, Sebastián JL, Pertusa C, et al. Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int 2002;89:671-80.
28. Lamm DL. Efficacy and safety of bacille Calmette-Guérin immunotherapy in superficial bladder cancer. Clin Infect Dis 2000;31 Suppl 3:S86-90.
29. van der Meijden AP, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV; EORTC Genito-Urinary Tract Cancer Group. Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 2003;44:429-34.
30. Lüftenegger W, Ackermann DK, Futterlieb A, Kraft R, Minder CE, Nadelhaft P, et al. Intravesical versus intravesical plus intradermal bacillus Calmette-Guerin: A prospective randomized study in patients with recurrent superficial bladder tumors. J Urol 1996;155:483-7.
31. Palou J, Angerri O, Segarra J, Caparrós J, Guirado L, Diaz JM, et al. Intravesical bacillus Calmette-Guèrin for the treatment of superficial bladder cancer in renal transplant patients. Transplantation 2003;76:1514-6.
32. Horinaga M, Fukuyama R, Iida M, Yanaihara H, Nakahira Y, Nonaka S, et al. Enhanced antitumor effect of coincident intravesical gemcitabine plus BCG therapy in an orthotopic bladder cancer model. Urology 2010;76:1267.e1-6.
33. Houghton BB, Chalasani V, Hayne D, Grimison P, Brown CS, Patel MI, et al. Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: A systematic review with metaanalysis. BJU Int 2013;111:977-83.
34. Kaasinen E, Wijkström H, Malmström PU, Hellsten S, Duchek M, Mestad O, et al. Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: A nordic study. Eur Urol 2003;43:637-45.
35. Rajala P, Kaasinen E, Raitanen M, Liukkonen T, Rintala E; Finnbladder Group. Perioperative single dose instillation of epirubicin or interferon-alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: A prospective randomized multicenter study - FinnBladder III long-term results. J Urol 2002;168:981-5.
36. Giannakopoulos S, Gekas A, Alivizatos G, Sofras F, Becopoulos T, Dimopoulos C. Efficacy of escalating doses of intravesical interferon alpha-2b in reducing recurrence rate and progression in superficial transitional cell carcinoma. Br J Urol 1998;82:829-34.
37. Glashan RW. A randomized controlled study of intravesical alpha-2binterferon in carcinoma in situ of the bladder. J Urol 1990;144:658-61.
38. Jimenez-Cruz JF, Vera-Donoso CD, Leiva O, Pamplona M, Rioja-Sanz LA, Martinez-Lasierra M, et al. Intravesical immunoprophylaxis in recurrent superficial bladder cancer (Stage T1): Multicenter trial comparing bacille Calmette-Guérin and interferon-alpha. Urology 1997;50:529-35.
39. Lamm D, Brausi M, O'Donnell MA, Witjes JA. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer. Urol Oncol 2014;32:35.e21-30.
40. Filion MC, Phillips NC. Therapeutic potential of mycobacterial cell wall-DNA complexes. Expert Opin Investig Drugs 2001;10:2157-65.
41. Filion MC, Filion B, Reader S, Ménard S, Phillips NC. Modulation of interleukin-12 synthesis by DNA lacking the CpG motif and present in a mycobacterial cell wall complex. Cancer Immunol Immunother 2000;49:325-34.
42. Reader S, Ménard S, Filion B, Filion MC, Phillips NC. Pro-apoptotic and immunomodulatory activity of a mycobacterial cell wall-DNA complex towards LNCaP prostate cancer cells. Prostate 2001;49:155-65.
43. Morales A, Herr H, Steinberg G, Given R, Cohen Z, Amrhein J, et al. Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Guérin. J Urol 2015;193:1135-43.
44. LaRue H, Ayari C, Bergeron A, Fradet Y. Toll-like receptors in urothelial cells - Targets for cancer immunotherapy. Nat Rev Urol 2013;10:537-45.
45. Boehm BE, Svatek RS. Novel therapeutic approaches for recurrent nonmuscle invasive bladder cancer. Urol Clin North Am 2015;42:159-68, vii.
46. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014;515:558-62.
47. Carneiro BA, Meeks JJ, Kuzel TM, Scaranti M, Abdulkadir SA, Giles FJ. Emerging therapeutic targets in bladder cancer. Cancer Treat Rev 2015;41:170-8.
48. Newton MR, Askeland EJ, Andresen ED, Chehval VA, Wang X, Askeland RW, et al. Anti-interleukin-10R1 monoclonal antibody in combination with bacillus Calmette - Guérin is protective against bladder cancer metastasis in a murine orthotopic tumour model and demonstrates systemic specific anti-tumour immunity. Clin Exp Immunol 2014;177:261-8.
49. Scheidhauer K, Seidl C, Morgenstern A, Bruchertseifer F, Apostolidis C, Autenrieth M, et al. Treatment of bladder cancer with Bi-213-anti-EGFRMAb - A pilot study. J Nucl Med 2014;55 Suppl 1:639. Available from: http://jnm.snmjournals.org/gca?allch=&submit=Go&gca=jnumed%3B 55%2Fsupplement-1%2F639. [Last accessed on 2015 Sep 19].
50. Autenrieth M, Kurtz F, Horn T, Seidl C, Morgenstern A, Bruchertseifer F, et al. Intravesikale-Strahler-Radioimmuntherapie mit Bi-213-anti-EGFR-mAb beim Carcinoma in situ-Rezidiv nach BCGTherapie: Eine Alternative zur Zystektomie? Available from http://www.egms.de/static/de/meetings/oegu2015/15oegu06.shtml [Last accessed on 2015 Sep 19].
51. Waidelich R, Stepp H, Baumgartner R, Weninger E, Hofstetter A, Kriegmair M. Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer. J Urol 2001;165:1904-7.
52. Pinthus JH, Bogaards A, Weersink R, Wilson BC, Trachtenberg J. Photodynamic therapy for urological malignancies: Past to current approaches. J Urol 2006;175:1201-7.
53. Gollnick SO, Brackett CM. Enhancement of anti-tumor immunity by photodynamic therapy. Immunol Res 2010;46:216-26.
54. Nseyo UO, Shumaker B, Klein EA, Sutherland K. Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder. Bladder Photofrin Study Group. J Urol 1998;160:39-44.
55. Bader MJ, Stepp H, Beyer W, Pongratz T, Sroka R, Kriegmair M, et al. Photodynamic therapy of bladder cancer - a phase I study using hexaminolevulinate (HAL). Urol Oncol 2013;31:1178-83.
56. Lange N, Jichlinski P, Zellweger M, Forrer M, Marti A, Guillou L, et al. Photodetection of early human bladder cancer based on the fluorescence of 5-aminolaevulinic acid hexylester-induced protoporphyrin IX: A pilot study. Br J Cancer 1999;80:185-93.